What is Edison Pharmaceuticals?
Headquartered in Lakeville, Massachusetts, Edison Pharmaceuticals operates as a specialized entity within the pharmaceutical sector. With a workforce of 20 to 49 employees and annual revenues ranging between 10M and 25M, the company maintains a lean, high-impact operational model. The firm focuses on pharmaceutical innovation, leveraging its strategic position to address unmet medical needs. Its market presence is characterized by a disciplined approach to drug development and a commitment to long-term value creation, which has historically resonated with both trade partners and institutional investors seeking exposure to high-growth life sciences assets.
How much funding has Edison Pharmaceuticals raised?
Edison Pharmaceuticals has raised a total of $87M across 7 funding rounds:
Series A
$2.8M
Series B
$4.3M
Series C
$2.8M
Series D
$3M
Series E
$4.1M
Series F
$20M
Private Equity
$50M
Series A (2005): $2.8M with participation from Paul Avery
Series B (2007): $4.3M, investors not publicly disclosed
Series C (2009): $2.8M, investors not publicly disclosed
Series D (2010): $3M, investors not publicly disclosed
Series E (2012): $4.1M, investors not publicly disclosed
Series F (2012): $20M with participation from Mitsui & Co.
Private Equity (2014): $50M led by Dainippon Sumitomo Pharma Co., Ltd
Key Investors in Edison Pharmaceuticals
Dainippon Sumitomo Pharma Co., Ltd
Sumitomo Dainippon Pharma Co Ltd is a major pharmaceutical entity based in Osaka, Japan, with a significant workforce and extensive experience in global drug development.
Mitsui & Co.
Mitsui & Co. is a global trading and investment firm that focuses on industry growth, infrastructure, and the delivery of healthcare solutions through a vast international network.
Paul Avery
An individual investor who provided early-stage backing to support the foundational development of the company.
What's next for Edison Pharmaceuticals?
Looking ahead, the recent capital injection is expected to catalyze the next phase of Edison Pharmaceuticals' growth strategy. With a history of successful financing rounds dating back to 2005, the company is well-positioned to accelerate its pipeline development and potentially expand its market reach. The involvement of major global players suggests a strategic alignment aimed at enhancing operational efficiency and scaling commercialization efforts. As the firm transitions into this new chapter, stakeholders will likely monitor its ability to convert these financial resources into tangible clinical milestones and sustained revenue growth, further solidifying its standing in the global pharmaceutical market.
See full Edison Pharmaceuticals company page
